Han Nan Asia Pharmaceuticals Inc.
Han Nan Asia Pharmaceuticals Inc., headquartered in [location], is a prominent player in the pharmaceutical industry, specialising in the development and distribution of innovative healthcare solutions. Founded in [year], the company has established a strong presence in major operational regions across Asia, focusing on both prescription and over-the-counter medications. With a commitment to quality and efficacy, Han Nan Asia Pharmaceuticals offers a diverse range of products, including [core products/services], which are distinguished by their unique formulations and adherence to stringent regulatory standards. The company has achieved significant milestones, positioning itself as a trusted name in the market, recognised for its contributions to improving patient outcomes. Through continuous research and development, Han Nan Asia Pharmaceuticals remains dedicated to advancing healthcare and meeting the evolving needs of the industry.
DitchCarbon Score
How does Han Nan Asia Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Han Nan Asia Pharmaceuticals Inc.'s score of 3 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Han Nan Asia Pharmaceuticals Inc.'s reported carbon emissions
In 2021, Han Nan Asia Pharmaceuticals Inc. reported total carbon emissions of approximately 15,771,225,000 kg CO2e. This figure includes Scope 1 emissions of about 886,000 kg CO2e, primarily from stationary combustion (809,000 kg CO2e) and mobile combustion (42,000 kg CO2e). Scope 2 emissions totalled around 2,337,000 kg CO2e, with purchased electricity contributing approximately 423,000 kg CO2e and purchased steam accounting for about 1,624,000 kg CO2e. The company’s Scope 3 emissions were significant, reaching approximately 1,573,898,000 kg CO2e, with the largest contributions from purchased goods and services (about 1,488,635,000 kg CO2e) and employee commuting (approximately 1,406,000 kg CO2e). Han Nan Asia Pharmaceuticals has set ambitious climate commitments, aiming for a 42% absolute reduction in Scope 1 and 2 greenhouse gas emissions by 2030, targeting a reduction to 1,900 metric tons CO2e from a baseline of 3,200 metric tons CO2e established in 2021. This target aligns with the Science Based Targets initiative (SBTi) requirements for near-term targets. The company has demonstrated a commitment to transparency and accountability in its emissions reporting, with comprehensive disclosures across all three scopes of emissions. As of now, there are no cascaded emissions data from a parent or related organization, indicating that the reported figures are solely from Han Nan Asia Pharmaceuticals Inc. itself.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Scope 1 | 607,000 | 000,000 | 000,000 |
| Scope 2 | 2,748,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 2,445,000 | 0,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Han Nan Asia Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
